Mr O’Holla has an extensive background in the fields of R&D, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its next-generation endovascular devices, the company said.
He chaired the technology and regulatory advisory committee at AdvaMed, a medical technology industry group for 13 years, and was a key figure in the construction of the Medical Device User Fee and Modernization Act of 2002, which amended and refined food and drug law related to medical devices.
Martin Dieck, president and CEO of Nfocus, said: “Bob O’Holla brings an unmatched wealth of regulatory and compliance experience to Nfocus, having served 18 of his last 30 years in the industry in the role of worldwide vice president of regulatory affairs, medical devices, for Johnson & Johnson. His disciplined and strategic approach to the product development and approval processes set him apart as a worldwide expert. We are thrilled to welcome him to Nfocus Neuromedical.”